🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥Can we predict relapse in colon cancer before surgery❓Together with HMar Research Institute and Quibim, we built an AI-radiomics model that identifies high-risk patients from pre-op CT scans. 📌Published in ESMO Open 🔗sciencedirect.com/science/articl…

🚨 Patterns of recurrence in esophageal adenocarcinoma comparing FLOT vs CROSS— ESOPEC trial update 💥 ascopubs.org/doi/10.1200/JC… ▪️Locoregional recurrence (3-yr CI): FLOT 20.2% vs CROSS 17.4% (NS) ▪️Distant recurrence (3-yr CI): FLOT 31.5% vs CROSS 47.2% (p=.002) CROSS-ing paths,

📍Nonoperative Management of Mismatch Repair–Deficient Tumors nejm.org/doi/full/10.10… 👉Dostarlimab: 100% de respuesta clínica completa en cáncer de recto dMMR/MSI-H. 92% SLR a 2 años sin cirugía 👉Una opción terapéutica real, y menos invasiva, para este subgrupo de pacientes

📍Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. CABINET nejm.org/doi/full/10.10… 👉Cabozantinib mejora SLP en tumores neuroendocrinos pancreáticos (13,8 vs 4,4m; HR 0,23) y extrapancreáticos (8,4 vs 3,9m; HR 0,38), con independencia de su funcionalidad

📍ESTUDIO PANDORA II 🎯principal: evaluar la tasa de respuesta patológica completa (RCp) al añadir durvalumab al tratamiento neoadyuvante con quimiorradioterapia de ciclo largo esmoopen.com/article/S2059-… 👉Tasa de RCp del 34,5% 👉Mayor tasa de RCp 👉Perfil de toxicidad aceptable

📍Nonoperative Management of Mismatch Repair–Deficient Tumors nejm.org/doi/full/10.10… 👉Dostarlimab: 100% de respuesta clínica completa en cáncer de recto dMMR/MSI-H. 92% SLR a 2 años sin cirugía 👉Una opción terapéutica real, y menos invasiva, para este subgrupo de paciente

📈 Early-Onset GI Cancers. A review. 🔗 jamanetwork.com/journals/jamao… In 2022, CRC led (54%), followed by gastric (24%), esophageal (13%), and pancreatic (9%). 🧬 15–30% have germline variants 📉 Prognosis same or worse than later-onset ⚠️ Prevention & early detection needed

🧪 Gastric cancer 🔗 thelancet.com/journals/lance… ~1M new cases & >650k deaths/year 📈 Rising early-onset cases (<50y) ⚠️ Key risks: H. pylori, diet, obesity 🛠️ D2 surgery + chemo ± IO/targeted Rx 🔬 Future: early detection & precision medicine

🧪 Temporal dynamics of CLDN18.2 expression after zolbetuximab in gastric cancer 🔗 doi.org/10.1016/j.esmo… 📉 53% lost CLDN18.2 (≥75%) after treatment 📊 Expression preserved in 67%/73% with ≥40%/≥25% cut-offs 🎯 New CLDN18.2 drugs may suit pretreated pts

📢SAVE THE DATE ‼ 👉33 Grupo Español de Tratamiento de Tumores Digestivos International Symposium 📅10-11-12 Dec. 2025 Oviedo (Spain) 🗣️A meeting point for leading specialists who will present the latest data related to the progress in the investigation of the digestive tumours #TTD25 ttdgroup.org/formacion/simp…

🧬 New review on miR-184 in #HCC link.springer.com/article/10.100… This miRNA plays a dual role—as oncogene or tumor suppressor—depending on target context. It impacts key pathways (Wnt/β-catenin, JAK2/STAT3), and interacts with multiple circRNAs & lncRNAs. 🎯 A promising biomarker

Nieves Martinez Lago MD PhD Grupo Español de Tratamiento de Tumores Digestivos Grupo GITUD We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing oncodaily.com/insight/nieves…

🎬 ¡La 3ª edición de Nuevos abordajes en tumores GI no colorrectales ya está completa! Accede a todos los episodios y actualízate en HCC, gástrico y páncreas, con referentes como andres jmm , Ana Fernández Montes, MD,Phd, Teresa Macarulla y Fernando Rivera. Iniciativa científica